TEAEs and ASC
| n (%) | PFS (n=36) | AI (n=35) |
|---|---|---|
| ≥1 TEAE | 29 (80.6) | 29 (82.9) |
| ≥1 TEAE related to trial drug | 16 (44.4) | 20 (57.1) |
| ≥1 non-serious TEAE | 29 (80.6) | 29 (82.9) |
| ≥1 serious TEAE | 0 | 0 |
| ASC* | 14 (38.9) | 20 (57.1) |
| Injection site erythema | 13 (36.1) | 18 (51.4) |
| Injection site swelling | 3 (8.3) | 7 (20.0) |
| Injection site induration | 1 (2.8) | 4 (11.4) |
*Injection-site reactions are those events recorded within the electronic case report form “Administration site reactions” (narrow) list.